275 related articles for article (PubMed ID: 17576165)
1. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
[TBL] [Abstract][Full Text] [Related]
2. Ion transporters involved in acidification of the resorption lacuna in osteoclasts.
Henriksen K; Sørensen MG; Jensen VK; Dziegiel MH; Nosjean O; Karsdal MA
Calcif Tissue Int; 2008 Sep; 83(3):230-42. PubMed ID: 18787885
[TBL] [Abstract][Full Text] [Related]
3. Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.
Neutzsky-Wulff AV; Sørensen MG; Kocijancic D; Leeming DJ; Dziegiel MH; Karsdal MA; Henriksen K
BMC Musculoskelet Disord; 2010 Jun; 11():109. PubMed ID: 20515459
[TBL] [Abstract][Full Text] [Related]
4. Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption.
Sørensen MG; Karsdal MA; Dziegiel MH; Boutin JA; Nosjean O; Henriksen K
BMC Musculoskelet Disord; 2010 Oct; 11():250. PubMed ID: 20977756
[TBL] [Abstract][Full Text] [Related]
5. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification.
Henriksen K; Sørensen MG; Nielsen RH; Gram J; Schaller S; Dziegiel MH; Everts V; Bollerslev J; Karsdal MA
J Bone Miner Res; 2006 Jan; 21(1):58-66. PubMed ID: 16355274
[TBL] [Abstract][Full Text] [Related]
6. Characterization of acid flux in osteoclasts from patients harboring a G215R mutation in ClC-7.
Henriksen K; Gram J; Neutzsky-Wulff AV; Jensen VK; Dziegiel MH; Bollerslev J; Karsdal MA
Biochem Biophys Res Commun; 2009 Jan; 378(4):804-9. PubMed ID: 19070589
[TBL] [Abstract][Full Text] [Related]
7. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
Niikura K; Takano M; Sawada M
Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of osteoclast vacuolar H(+)-ATPase.
Farina C; Gagliardi S
Curr Pharm Des; 2002; 8(23):2033-48. PubMed ID: 12171517
[TBL] [Abstract][Full Text] [Related]
9. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
Nyman JK; Väänänen HK
Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
[TBL] [Abstract][Full Text] [Related]
10. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
Niikura K; Takeshita N; Takano M
J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
[TBL] [Abstract][Full Text] [Related]
11. Effects of diphyllin as a novel V-ATPase inhibitor on gastric adenocarcinoma.
Shen W; Zou X; Chen M; Liu P; Shen Y; Huang S; Guo H; Zhang L
Eur J Pharmacol; 2011 Sep; 667(1-3):330-8. PubMed ID: 21645513
[TBL] [Abstract][Full Text] [Related]
12. Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts.
Sahara T; Itoh K; Debari K; Sasaki T
Anat Rec A Discov Mol Cell Evol Biol; 2003 Feb; 270(2):152-61. PubMed ID: 12524690
[TBL] [Abstract][Full Text] [Related]
13. Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption - a novel target for treatment of osteoporosis.
Thudium CS; Jensen VK; Karsdal MA; Henriksen K
Curr Protein Pept Sci; 2012 Mar; 13(2):141-51. PubMed ID: 22044152
[TBL] [Abstract][Full Text] [Related]
14. Antiviral efficacy of nanoparticulate vacuolar ATPase inhibitors against influenza virus infection.
Hu CJ; Chen YT; Fang ZS; Chang WS; Chen HW
Int J Nanomedicine; 2018; 13():8579-8593. PubMed ID: 30587980
[TBL] [Abstract][Full Text] [Related]
15. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
[TBL] [Abstract][Full Text] [Related]
16. Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption.
Wu H; Xu G; Li YP
J Bone Miner Res; 2009 May; 24(5):871-85. PubMed ID: 19113919
[TBL] [Abstract][Full Text] [Related]
17. Effects of Bafilomycin A1: an inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts.
Xu J; Feng HT; Wang C; Yip KH; Pavlos N; Papadimitriou JM; Wood D; Zheng MH
J Cell Biochem; 2003 Apr; 88(6):1256-64. PubMed ID: 12647307
[TBL] [Abstract][Full Text] [Related]
18. Bovine parathyroid hormone enhances osteoclast bone resorption by modulating V-ATPase through PTH1R.
Liu S; Zhu W; Li S; Ma J; Zhang H; Li Z; Zhang L; Zhang B; Li Z; Liang X; Shi W
Int J Mol Med; 2016 Feb; 37(2):284-92. PubMed ID: 26647715
[TBL] [Abstract][Full Text] [Related]
19. Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity.
Crasto GJ; Kartner N; Yao Y; Li K; Bullock L; Datti A; Manolson MF
J Cell Biochem; 2013 Apr; 114(4):929-41. PubMed ID: 23129004
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.
Chen HW; Cheng JX; Liu MT; King K; Peng JY; Zhang XQ; Wang CH; Shresta S; Schooley RT; Liu YT
Antiviral Res; 2013 Sep; 99(3):371-82. PubMed ID: 23820269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
